Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Aurinia Pharmaceuticals Inc AUPH

Aurinia Pharmaceuticals Inc. is a fully integrated biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is primarily engaged in the development of its pipeline asset AUR200, a differentiated, potential next generation therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand). The Company contracted with Otsuka Pharmaceutical Co., Ltd. (Otsuka) as a collaboration partner for the development and commercialization of LUPKYNIS in the Otsuka Territories. It sells LUPKYNIS (voclosporin) primarily to specialty pharmacies and a specialty distributor and directly to its ex-U.S. partner, Otsuka.


NDAQ:AUPH - Post by User

Bullboard Posts
Post by Moneyday0on Aug 15, 2016 3:31pm
399 Views
Post# 25143325

What what what - results were incredible

What what what - results were incredibleWhat happened that I missed. FDA has no choice but to accept. This is enhanced life expectancy for shoot sakes and at minimum non invasive and a combo cure to reduced infringement on the human body systems. Asian deaths explained as NON related. Results again were just amazing. Definitely goin to be a merger coming up as this is the next gotta have drug for the big boy companies. Now PLEASE explain what is so bad with results - anyone - Please... Been loading up all day. Listen to the call, all the questions and re-read results. Nothing to indicate this was a bust phase 2b. Actually amazing for anyone with LN. Win for patients, win for the future to enhance immunotherapy and win for the company to keep investing in research and twigging of the V product for humanity. How can this be bad for shareholders?
Bullboard Posts